Global Medicine for the Treatment of Advanced Thyroid Cancer Market Research Report 2022
Thyroid cancer is the most common endocrine tumor. Four targeted agents (vandetanib, cabozantinib, sorafenib, and lenvatinib) have attained regulatory approval for advanced thyroid cancer, and several other related agents are now commonly used off-label as first- and second-line treatments for selected patients.
Due to the COVID-19 pandemic, the global Medicine for the Treatment of Advanced Thyroid Cancer market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Medicine for the Treatment of Advanced Thyroid Cancer market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Medicine for the Treatment of Advanced Thyroid Cancer landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Cabozantinib accounting for % of the Medicine for the Treatment of Advanced Thyroid Cancer global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Combination therapy segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Medicine for the Treatment of Advanced Thyroid Cancer include Bayer, AstraZeneca, Sanofi, Exelixis Inc., Ipsen Pharma and Eisai Inc, etc. In terms of revenue, the global 3 largest players have a % market share of Medicine for the Treatment of Advanced Thyroid Cancer in 2021.
This report focuses on Medicine for the Treatment of Advanced Thyroid Cancer volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Medicine for the Treatment of Advanced Thyroid Cancer market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Medicine for the Treatment of Advanced Thyroid Cancer Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Cabozantinib
Sorafenib
Vandetanib
Lenvatinib
Segment by Application
Combination therapy
Solo Medication
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Bayer
AstraZeneca
Sanofi
Exelixis Inc.
Ipsen Pharma
Eisai Inc
Due to the COVID-19 pandemic, the global Medicine for the Treatment of Advanced Thyroid Cancer market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Medicine for the Treatment of Advanced Thyroid Cancer market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Medicine for the Treatment of Advanced Thyroid Cancer landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Cabozantinib accounting for % of the Medicine for the Treatment of Advanced Thyroid Cancer global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Combination therapy segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Medicine for the Treatment of Advanced Thyroid Cancer include Bayer, AstraZeneca, Sanofi, Exelixis Inc., Ipsen Pharma and Eisai Inc, etc. In terms of revenue, the global 3 largest players have a % market share of Medicine for the Treatment of Advanced Thyroid Cancer in 2021.
This report focuses on Medicine for the Treatment of Advanced Thyroid Cancer volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Medicine for the Treatment of Advanced Thyroid Cancer market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Medicine for the Treatment of Advanced Thyroid Cancer Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Cabozantinib
Sorafenib
Vandetanib
Lenvatinib
Segment by Application
Combination therapy
Solo Medication
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Bayer
AstraZeneca
Sanofi
Exelixis Inc.
Ipsen Pharma
Eisai Inc
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
